BWXT Agrees to Sell Medical Business for Up to $800 Million
BWX Technologies has agreed to sell its medical business, including BWXT Medical and Kinectrics' stable isotopes operations, to Nordic Capital in a deal valued at up to $800 million. The transaction is expected to allow BWXT to focus on core defense-related nuclear technologies while divesting non-core assets. The sale includes the company's production of medical isotopes used for diagnostic imaging and cancer treatment. Nordic Capital will take over operations, which are based in Canada and the U.S., with plans to continue supplying critical materials to healthcare providers globally.
Tickers: $BWXT